Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-9 of 9 for your search:
Drug:
allogeneic tumor cell vaccine
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
100798-HMO-CTIL
, NCT00148993
2.
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
55 and over
Sponsor:
Other
Protocol IDs:
191199-HMO-CTIL
, NCT00162513
3.
A Phase I/Ii Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 21
Sponsor:
Other
Protocol IDs:
22053
, NCT00703222
4.
Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
0359-08-HMO-CTIL
, NCT00722228
5.
Phase II Study of Vaccine Therapy Comprising Allogeneic Tumor Cells and GM.CD40L in Combination With Tretinoin and Cyclophosphamide in Patients Who Have Completed First-Line Chemotherapy for Metastatic Adenocarcinoma of the Lung
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MCC-14744
, MCC 14744, MCC-104490, MCC-0534-NE, NIH-OBA-0608-801, NCT00601796
6.
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CTN-0505
, UKIRB 06-0716-F3R, ULIRB 065.07, CIRB 1079747, NCT00654030
7.
Phase II Randomized Study of an Allogeneic Prostate Cancer Cell Vaccine With Versus Without Autologous Myeloid Dendritic Cells in Patients With Androgen-Independent Non-Metastatic Prostate Carcinoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0554
, MC0554, MAYO-06-004659, NCT00814892
8.
Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
40 and over
Sponsor:
Other
Protocol IDs:
06-275
, NCT00487305
9.
Phase I Study of Adjuvant Cyclophosphamide and Adjuvant Vaccine Therapy Comprising Allogeneic Colon Cancer Cells and K562/GM-CSF Cells in Patients With Resected Hepatic Metastases Secondary to Colorectal Cancer
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0745
, J0745, JHOC-NA_00009345, NCT00656123
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute